Unique ID issued by UMIN | UMIN000014515 |
---|---|
Receipt number | R000016471 |
Scientific Title | Evaluation of perioperative pregabalin for prevention and attenuation of postoperative shoulder pain after thoracotomy in patients with lung cancer |
Date of disclosure of the study information | 2014/07/09 |
Last modified on | 2015/01/09 12:34:07 |
Evaluation of perioperative pregabalin for prevention and attenuation of postoperative shoulder pain after thoracotomy in patients with lung cancer
Evaluation of perioperative pregabalin for prevention and attenuation of postoperative shoulder pain after thoracotomy in patients with lung cancer
Evaluation of perioperative pregabalin for prevention and attenuation of postoperative shoulder pain after thoracotomy in patients with lung cancer
Evaluation of perioperative pregabalin for prevention and attenuation of postoperative shoulder pain after thoracotomy in patients with lung cancer
Japan |
Lung cancer
Neuropathic Pain
Postoperative shoulder pain
Chest surgery | Anesthesiology | Adult |
Malignancy
NO
The aim of this comparative trail was to test whether the addition of pregabalin 150 mg/day (the maximum dose is 300 mg/day) in to the treatment of shoulder pain in patients who had undergone thoracic surgery for lung cancer would have a significant impact on the Visual Analog Scale (VAS) scores.
Safety,Efficacy
Shoulder pain severity was measured using a 100-mm visual analog scale (VAS) scoring system until post operative days 7.
Interventional
Parallel
Non-randomized
Open -no one is blinded
Active
2
Treatment
Medicine |
Patients received pregabalin 150 mg po 10-16 h after surgery and then non-steroidal anti-inflammatory drugs (NSAIDs) po 2 hours later. (maximum dose is 300 mg/day)
only NSAIDs po (loxoprofen 180mg/day)
20 | years-old | <= |
Not applicable |
Male and Female
1)Histologically or cytologically confirmed lung cancer
2)without indication for curative radiation therapy
3)Performance Status(ECOG) 0-1
4)Patients aged 20 years or older
5)Sufficient function of main organ and normal hematopoietic function, normal liver function and normal renal function filled the following
criteria
*Leukocyte counts >= 3,000/mm3
*Neutrophil counts >= 1,500/mm3
*Platelets >= 100,000/mm3
*Hemoglobin concentration >= 9.0 g/dL
*AST and ALT, x 2.5 of upper limit of
normal (ULN) or less.
*Total bilirubin <=1.5mg/dL.
*Serum creatinin, x 1.5 of ULN or less.
*Electrocardiogram Nomal
*SpO2 >=90% or SaPO2 >=65mmHg
*Protein urea >= 1+
6)Patients providing written informed consent
Inappropriate patients for this study judged by the physicians
40
1st name | |
Middle name | |
Last name | Kazuhiro Imai |
Akita University Graduate School of Medicine
General Thoracic Surgery (and Breast & Endocrine Surgery)
1-1-1 Hondo, Akita, Japan
018-884-6132
i-karo@mui.biglobe.ne.jp
1st name | |
Middle name | |
Last name | Kazuhiro Imai |
Akita University Graduate School of Medicine
General Thoracic Surgery (and Breast & Endocrine Surgery)
1-1-1 Hondo, Akita, Japan
018-884-6132
i-karo@mui.biglobe.ne.jp
Akita University Graduate School of Medicine
Akita University Graduate School of Medicine
Self funding
NO
2014 | Year | 07 | Month | 09 | Day |
Published
Completed
2012 | Year | 04 | Month | 01 | Day |
2012 | Year | 05 | Month | 01 | Day |
2014 | Year | 07 | Month | 09 | Day |
2015 | Year | 01 | Month | 09 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000016471
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |